Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
40 participants
INTERVENTIONAL
2009-07-31
2023-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study will have several aims.
One aim is to examine the effect of 72 hours of fasting on fibroblast growth factor-21 (FGF-21) levels. Participants will spend 3 days and nights in the Clinical Research Center at the Beth Israel Deaconess Medical Center in Boston, MA. Daily blood samples will be taken. Two fat samples will be taken prior to and at the end of the fast. A subset of participants will also have two MRIs, one prior to and one at the end of the fast. We will study healthy adults and obese adults with liver-biopsy-diagnosed non-alcoholic fatty liver disease (NAFLD). THIS STUDY ARM IS CURRENTLY NOT RECRUITING
Another aim is to examine the effect of low-calorie diet on FGF-21 levels. Subjects will follow a hypocaloric diet that will be designed to achieve 3-5% weight loss. We will enroll participants with liver-biopsy-diagnosed non-alcoholic fatty liver disease. Participants will report weekly to the Clinical Research Center at Beth Israel Deaconess Medical Center for weight measurements. Blood will be drawn before and after the weight loss. Participants will also have an MRI before and after the weight loss.
THIS ARM IS CURRENTLY NOT RECRUITING
Another aim of the study is to examine the effect of acute ingestion of glucose, fructose, and other sugars on serum FGF21 levels. Subjects in this study will be lean volunteers and individuals with metabolic syndrome.
THIS ARM IS CURRENTLY RECRUITING
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Carbohydrate-restricted Diet to Reverse Fatty Liver in Adolescents With Obesity
NCT02787668
Effects of Carnitine Supplementation on Liver and Muscle
NCT03439917
A Feasibility Trial of OCM Supplements for the Treatment of NAFLD
NCT05720702
Effect of VLCD on the Reduction of Liver Steatosis and Fibrosis in Subjects With Obesity and NAFLD
NCT04861571
Effect of Bile Acids on Satiety, Cell Function and Body Weight in Patients With Obesity and Abnormal Satiety Phenotype
NCT05314374
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Fasting (Healthy).
Participants will fast for 72 hours during an inpatient stay at the Beth Israel Deaconess Medical Center in Boston, MA. Blood samples will be collected daily and two fat samples will be obtained by a trained surgeon. (We are no longer recruiting for Study Arm A).
Fasting
Participants will fast for 72 hours and may consume only water and vitamins.
Fasting
Participants will fast for 72 hours and may consume only water and vitamins.
Fasting (NAFLD)
Participants with liver-biopsy diagnosed non-alcoholic fatty liver disease (NAFLD) will fast for 72 hours during an inpatient stay at the Beth Israel Deaconess Medical Center in Boston, MA. Blood samples will be collected daily, and participants will have an MRI before and after the fast.
Fasting
Participants will fast for 72 hours and may consume only water and vitamins.
Hypocaloric diet (NAFLD)
Participants will follow a low-calorie diet until they lose 3-5% of their body weight. Participants will have weekly outpatient visits at Beth Israel Deaconess Medical Center in Boston, MA for weight measurements. Participants will have blood drawn before and after the diet. Participants will also have an MRI before and after the diet.
Diet
Participants will follow a low-calorie diet until they lose 3-5% of their body weight.
Oral carbohydrate challenge
Participants will fast for 16 hours overnight then ingest drinks containing fructose, glucose or a mixture of fructose and glucose. Blood will be drawn postprandially at specified timepoints for up to 5 hours
oral carbohydrate challenge
Participants will fast for 16 hours and then drink a beverage containing glucose, fructose or a mixture of both
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fasting
Participants will fast for 72 hours and may consume only water and vitamins.
Fasting
Participants will fast for 72 hours and may consume only water and vitamins.
Diet
Participants will follow a low-calorie diet until they lose 3-5% of their body weight.
oral carbohydrate challenge
Participants will fast for 16 hours and then drink a beverage containing glucose, fructose or a mixture of both
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body Mass Index 21-26 kg/m\^2
* Ability to give informed consent
* Ability to follow verbal and written instructions in English
* Age 18-60
* BMI 25-45 kg/m\^2
* Known nonalcoholic fatty liver disease based on liver biopsy
* Ability to give informed consent
* Ability to follow verbal and written instructions in English
Exclusion Criteria
* Coronary heart disease (history of myocardial infarction, unstable angina pectoris, or congestive heart failure)
* Tobacco, marijuana, or intravenous drug use within 1 year of screening visit
* Recent weight change (\>3 kg within 6 months of screening visit)
* Malignancy treated with chemotherapy within past 3 years
* History of depression, psychosis, or other psychiatric illness requiring hospitalization
* History of hyperthyroidism
* Renal insufficiency (creatinine clearance \< 50 ml/min)
* Transaminases \> 2X above the normal range
* Known liver disease
* Pregnancy within 12 months of screening visit
* Lactation within 12 months of screening visit
* Failure to use medically approved contraceptive methods (oral contraceptive, 2 barrier methods, surgical sterilization)
* History of an eating disorder (anorexia, bulimia, or laxative abuse)
* History of surgery for the treatment of obesity (gastric banding, gastric bypass, gastric stapling)
* New diagnosis of hypothyroidism within 1 year of screening visit or change in dose of thyroid hormone within 3 months of screening visit
* History of alcohol abuse within the past 3 years
* History of keloid formation
* History of allergy to lidocaine or marcaine
* Use of plavix, coumadin, or heparin
72-hour fast or hypocaloric diet in subjects with non-alcoholic fatty liver disease (NAFLD) (Study Arms B \& C):
* Type I diabetes mellitus diagnosed according to the American Diabetes Association criteria or Type II diabetes mellitus with A1c \> 7.5% or taking metformin or thiazolidinediones
* Coronary Heart Disease (history of myocardial infarction, unstable angina pectoris, or congestive heart failure)
* Uncontrolled hypertension (BP \> 150/90 mmHg on or off antihypertensive medication)
* Tobacco, marijuana, or intravenous drug use within 1 year of screening visit
* Recent weight change (\> 3 kg within 6 months of screening visit)
* Malignancy treated with chemotherapy within the past 3 years
* History of depression, psychosis, or other psychiatric illness requiring hospitalization
* History of hypo or hyperthyroidism
* Renal insufficiency (creatinine clearance \< 50 ml/min)
* Pregnancy within 12 months of screening visit
* Lactation within 12 months of screening visit
* Failure to use medically approved contraceptive methods (oral contraceptive, 2 barrier methods, surgical sterilization)
* History of an eating disorder (anorexia, bulimia, or laxative abuse)
* History of surgery for the treatment of obesity (gastric banding, gastric bypass, gastric stapling)
* New diagnosis of hypo or hyperthyroidism within 1 year of screening visit or change in dose of thyroid hormone within 3 months of screening visit
* History of alcohol abuse within the past 3 years
* Cardiac pacemaker or aneurysm clips
* Metal implants in the body (pins, plates, shrapnel, intact bullets, IUD)
* Claustrophobia
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beth Israel Deaconess Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jody Dushay
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jody Dushay, MD
Role: PRINCIPAL_INVESTIGATOR
Beth Israel Deaconess Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2009P-000073
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.